Moody's: Royalty Pharma add-on is negative

Moody's Investors Service said that the proposed $100 million senior secured term loan add-on of RPI Finance Trust, a wholly-owned subsidiary of Royalty Pharma Unit Trust, is credit negative.

However, the add-on does not affect the rating, and RPI Finance Trust remains rated Baa2 with a stable rating outlook, the agency said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.